“…For example, fidarestat 113 and sorbinil 114 (anti-cancer/anti-diabetic) [113], brequinar 115 (antitumour/ immunosuppressive) [114], roflumilast 116 (anti-inflammatory/ chronic obstructive pulmonary diseases) [115], leflunomide 117 and VML-295 (LY293111) 118 (anti-cancer/psoriasis) [116], T0901317 119 and 2,4,6-trisubstituted pyridines 120 have been reported as potent farnesoid X receptor (FXR) modulators and they have emerged as target drugs for inflammation and cancers [117]. Fluorinated gonadotropin-releasing hormone (hGnRH) receptor antagonists 121 and 122 are in clinical development for the treatment of human reproductive diseases and gynecological cancer [118] and the steroid sulfatase inhibitors 123, 124 have recently been reported as more potent compounds than their non-fluorinated analogues 125, 126 as inhibitors of steroid dependent cancers [119].…”